Cardiac Toxicities Associated with Immune Checkpoints Inhibitors: Mechanisms, Manifestations and Management

다국어 초록 (Multilingual Abstract)

Immune checkpoint inhibitor (ICI) associated cardiovascular adverse events (CVAE) have become more frequent with the growing use of cancer immunotherapy. CVAEs include a wide spectrum of diseases such as myocarditis, pericarditis, heart failure, arrhythmias, coronary artery disease, and hypertension. The induction of cardiovascular side effects by ICI use is hypothesized to occur due to inflammation and immune dysregulation of normal tissue in response to immunotherapy. Management of ICI-associated CVAEs mitigates an overactive immune response by utilizing steroids, immunomodulatory drugs and hemodynamic stabilization. However, few controlled studies on the cardiovascular safety of ICIs exist and treatment of their side effects are mostly from limited case series. Our review seeks to provide the most recent understanding of ICI-associated CVAEs and their management.

참고문헌 (Reference)

1 Otsu K, "Vasospastic angina following immune checkpoint blockade" 41 : 1702-, 2020

2 McCarthy EF, "The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas" 26 : 154-158, 2006

3 Jeyakumar N, "The terrible triad of checkpoint inhibition : a case report of myasthenia gravis, myocarditis, and myositis induced by cemiplimab in a patient with metastatic cutaneous squamous cell carcinoma" 2020 : 5126717-, 2020

4 Mirabel M, "The risk of sudden cardiac death or ventricular arrhythmias on immune checkpoint inhibitors" 41 (41): ehaa946.34-, 2020

5 Tomiyama H, "The contribution of inflammation to the development of hypertension mediated by increased arterial stiffness" 6 : e005729-, 2017

6 Palaskas N, "Targeted cancer therapies with pericardial effusions requiring pericardiocentesis focusing on immune checkpoint inhibitors" 123 : 1351-1357, 2019

7 Tay RY, "Successful use of equine anti-thymocyte globulin(ATGAM)for fulminant myocarditis secondary to nivolumab therapy" 117 : 921-924, 2017

8 Fazel M, "Severe myositis, myocarditis, and myasthenia gravis with elevated anti-striated muscle antibody following single dose of ipilimumab-nivolumab therapy in a patient with metastatic melanoma" 2019 : 2539493-, 2019

9 Kolla BC, "Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy-a report of two cases" 4 : 80-, 2016

10 Chung ES, "Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure : results of the anti-TNF Therapy Against Congestive Heart Failure(ATTACH)trial" 107 : 3133-3140, 2003

11 Reddy N, "Progressive and reversible conduction disease with checkpoint inhibitors" 33 : 1335-, 2017

12 Kindermann I, "Predictors of outcome in patients with suspected myocarditis" 118 : 639-648, 2008

13 Yogasundaram H, "Plasma exchange for immune checkpoint inhibitorinduced myocarditis" 3 : 379-382, 2020

14 Bando S, "Plasma brain natriuretic peptide levels are elevated in patients with cancer" 12 : e0178607-, 2017

15 Saade A, "Pericardial effusion under nivolumab : case-reports and review of the literature" 7 : 266-, 2019

16 Schiopu SR, "Pembrolizumab-induced myocarditis in a patient with malignant mesothelioma : plasma exchange as a successful emerging therapy-case report" 10 : 1039-1046, 2021

17 Herbst RS, "Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer(KEYNOTE-010) : a randomised controlled trial" 387 : 1540-1550, 2016

18 Mok TS, "Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer(KEYNOTE-042) : a randomised, open-label, controlled, phase 3 trial" 393 : 1819-1830, 2019

19 Reck M, "Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer" 375 : 1823-1833, 2016

20 Hui R, "Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer : a phase 1 trial" 28 : 874-881, 2017

21 Tarrio ML, "PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis" 188 : 4876-4884, 2012

22 Behling J, "New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1(nivolumab)for metastatic melanoma" 27 : 155-158, 2017

23 Zimmer L, "Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy" 60 : 210-225, 2016

24 Xing Q, "Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1(sintilimab)therapy for lung adenocarcinoma" 8 : 250-, 2020

25 Lee Chuy K, "Myocarditis surveillance in patients with advanced melanoma on combination immune checkpoint inhibitor therapy : The Memorial Sloan Kettering Cancer Center experience" 24 : e196-7, 2019

26 Mahmood SS, "Myocarditis in patients treated with immune checkpoint inhibitors" 71 : 1755-1764, 2018

27 Mahmood SS, "Myocarditis in patients treated with immune checkpoint inhibitors" 71 : 1755-1764, 2018

28 Ji C, "Myocarditis in cynomolgus monkeys following treatment with immune checkpoint inhibitors" 25 : 4735-4748, 2019

29 Yanase T, "Myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma : a case report of successful management" 34 : 101508-, 2020

30 Kimura T, "Myasthenic crisis and polymyositis induced by one dose of nivolumab" 107 : 1055-1058, 2016

31 Brahmer JR, "Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy : American Society of Clinical Oncology Clinical Practice Guideline" 36 : 1714-1768, 2018

32 Tivol EA, "Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4" 3 : 541-547, 1995

33 Tajmir-Riahi A, "Life-threatening autoimmune cardiomyopathy reproducibly induced in a patient by checkpoint inhibitor therapy" 41 : 35-38, 2018

34 Yamaguchi S, "Late-onset fulminant myocarditis with immune checkpoint inhibitor nivolumab" 34 : 812-, 2018

35 Moslehi JJ, "Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis" 391 : 933-, 2018

36 Bu DX, "Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation" 31 : 1100-1107, 2011

37 Khan A, "Impact of pericardial effusion for patients receiving immune checkpoint inhibitors" 37 (37): e14121-, 2019

38 Ingelfinger JR, "Immunosuppression--the promise of specificity" 353 : 836-839, 2005

39 Balanescu DV, "Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis : pathway toward precision-based therapy" 47 : 107211-, 2020

40 Foks AC, "Immune checkpoint proteins : exploring their therapeutic potential to regulate atherosclerosis" 174 : 3940-3955, 2017

41 Lyon AR, "Immune checkpoint inhibitors and cardiovascular toxicity" 19 : e447-58, 2018

42 Lyon AR, "Immune checkpoint inhibitors and cardiovascular toxicity" 19 : e447-58, 2018

43 Liu S, "Immune checkpoint inhibitor-associated myocarditis with persistent troponin elevation despite abatacept and prolonged immunosuppression" 2 : 800-804, 2020

44 Frigeri M, "Immune checkpoint inhibitor-associated myocarditis : a new challenge for cardiologists" 34 : 92-, 2018

45 Zhou YW, "Immune checkpoint inhibitor-associated cardiotoxicity : current understanding on its mechanism, diagnosis and management" 10 : 1350-, 2019

46 Compton F, "Immune checkpoint inhibitor toxicity: a new indication for therapeutic plasma exchange?" jca.21890-, 2021

47 Palaskas N, "Immune checkpoint inhibitor myocarditis : pathophysiological characteristics, diagnosis, and treatment" 9 : e013757-, 2020

48 Awadalla M, "Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis" 75 : 467-478, 2020

49 Johnson DB, "Fulminant myocarditis with combination immune checkpoint blockade" 375 : 1749-1755, 2016

50 Garon EB, "Five-year overall survival for patients with advanced non-smallcell lung cancer treated with pembrolizumab : results from the phase I KEYNOTE-001 study" 37 : 2518-2527, 2019

51 de Azevedo SJ, "First-line atezolizumab monotherapy in patients with advanced BRAFV600 wild-type melanoma" 2021

52 Hauck AJ, "Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis : implications for role of sampling error" 64 : 1235-1245, 1989

53 Deftereos SN, "Effectiveness of rituximab in treating immune-checkpoint-inhibitorinduced immune-related adverse events : results of a systematic review" 32 : 282-283, 2021

54 Chen J, "Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a realworld cohort of hepatitis B virus associated hepatocellular carcinoma patients" 8 : 1187-, 2020

55 Chang CF, "Disease and its impact on politics, diplomacy, and the military : the case of smallpox and the Manchus(1613–1795)" 57 : 177-197, 2002

56 Baughman KL, "Diagnosis of myocarditis : death of Dallas criteria" 113 : 593-595, 2006

57 Caforio AL, "Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis : a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases" 34 : 2636-2648, 2013

58 Caforio AL, "Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis : a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases" 34 : 2636-2648, 2013

59 Wu LA, "Current role of endomyocardial biopsy in the management of dilated cardiomyopathy and myocarditis" 76 : 1030-1038, 2001

60 Lee J, "Contributions of PD-1/PD-L1 pathway to interactions of myeloid DCs with T cells in atherosclerosis" 46 : 169-176, 2009

61 Rota E, "Concomitant myasthenia gravis, myositis, myocarditis and polyneuropathy, induced by immune-checkpoint inhibitors : a life-threatening continuum of neuromuscular and cardiac toxicity" 14 : 4-5, 2018

62 Simon TA, "Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics : a multi-database real-world study" 21 : 228-, 2019

63 Escudier M, "Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity" 136 : 2085-2087, 2017

64 Kwon HJ, "Case reports of heart failure after therapy with a tumor necrosis factor antagonist" 138 : 807-811, 2003

65 Chen DY, "Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients : a review when cardiology meets immuno-oncology" 119 : 1461-1475, 2020

66 Salem JE, "Cardiovascular toxicities associated with immune checkpoint inhibitors : an observational, retrospective, pharmacovigilance study" 19 : 1579-1589, 2018

67 Hu JR, "Cardiovascular toxicities associated with immune checkpoint inhibitors" 115 : 854-868, 2019

68 Wang DY, "Cardiovascular toxicities associated with cancer immunotherapies" 19 : 21-, 2017

69 Ferreira VM, "Cardiovascular magnetic resonance in nonischemic myocardial inflammation : expert recommendations" 72 : 3158-3176, 2018

70 Zhang L, "Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis" 41 : 1733-1743, 2020

71 Jain V, "Cardiovascular complications associated with novel cancer immunotherapies" 19 : 36-, 2017

72 Amiri-Kordestani L, "Cardiovascular adverse events in immune checkpoint inhibitor clinical trials: a U.S. Food and Drug Administration pooled analysis" 36 (36): 3009-, 2018

73 Heinzerling L, "Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy" 4 : 50-, 2016

74 Hughes M, "Cardiac troponin testing in idiopathic inflammatory myopathies and systemic sclerosis-spectrum disorders : biomarkers to distinguish between primary cardiac involvement and low-grade skeletal muscle disease activity" 74 : 795-798, 2015

75 Agrawal N, "Cardiac toxicity associated with immune checkpoint inhibitors : case series and review of the literature" 12 : 260-276, 2019

76 Alvarez-Cardona Jose A, "Cardiac biomarkers during cancer therapy" 2 : 791-794, 2020

77 Jain V, "Autoimmune myocarditis caused by immune checkpoint inhibitors treated with antithymocyte globulin" 41 : 332-335, 2018

78 Nishimura H, "Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice" 291 : 319-322, 2001

79 Lee MS, "Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma(GO30140) : an open-label, multicentre, phase 1b study" 21 : 808-820, 2020

80 Chen W, "Assessment of myocarditis: cardiac MR, PET/CT, or PET/MR?" 21 : 76-, 2019

81 Esfahani K, "Alemtuzumab for immunerelated myocarditis due to PD-1 therapy" 380 : 2375-2376, 2019

82 Massin M, "Acute myocarditis with very high troponin but no ventricular dysfunction" 56 : 582-583, 2017

83 Tadokoro T, "Acute lymphocytic myocarditis with anti-PD-1 antibody nivolumab" 9 : e003514-, 2016

84 Läubli H, "Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma" 3 : 11-, 2015

85 Cautela J, "Acute coronary syndrome with immune checkpoint inhibitors : a proof-of-concept case and pharmacovigilance analysis of a life-threatening adverse event" 36 : 476-481, 2020

86 Salem JE, "Abatacept for severe immune checkpoint inhibitor-associated myocarditis" 380 : 2377-2379, 2019

87 Blair HA, "Abatacept : a review in rheumatoid arthritis" 77 : 1221-1233, 2017

88 Antman EM, "ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(Writing Committee to Revise the 1999Guidelines for the Management of Patients With Acute Myocardial Infarction)" 110 : 588-636, 2004

89 Nykl R, "A unique reason for coronary spasm causing temporary ST elevation myocardial infarction(inferior STEMI)-systemic inflammatory response syndrome after use of pembrolizumab" 2 : e100-2, 2017

90 Wei SC, "A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention" 11 : 614-625, 2021

91 Al-Khatib SM, "2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death : executive summary : a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society" 15 : e190-252, 2018

92 Yancy CW, "2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America" 136 : e137-61, 2017

93 January CT, "2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation : executive summary : a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society" 130 : 2071-2104, 2014

94 Amsterdam EA, "2014 AHA/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines" 64 : e139-228, 2014